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Abstract 
New antibacterial drugs are needed to keep up with the alarming increase in infections and 
incidence.  Historically, the majority of clinically useful drugs have been obtained from 
terrestrial natural sources such as plants and microorganisms.  Today such terrestrial sources of 
drugs are diminishing, owing to rediscovery of known compounds.  Fortunately marine 
microorganisms are an emerging and underdeveloped source of novel compounds with 
promising pharmaceutical potential.  We explored the hypothesis that Florida marine bacteria 
produce compounds that may inhibit bacterial growth/survival or biofilm formation, an 
aggregation of bacteria tightly adhered to a surface.   Through repetitive plating, 57 pure 
bacterial cultures were obtained from marine sediment samples from coastal northeast Florida 
and the Florida Keys, chemically extracted, and these extracts subjected to assays for inhibition 
of bacterial growth and biofilm formation in the model human pathogenic bacteria 
Staphylococcus aureus and Pseudomonas aeruginosa.  While these chemical extracts exhibited 
minimal inhibition of P. aeruginosa and S. aureus growth, seven of the 57 marine bacterial 
extracts significantly inhibited formation of P. aeruginosa biofilms relative to no extract 
controls.  Through sequencing of 16S rRNA genes, four of these natural product-producing 
marine bacterial strains were assigned as Bacillus spp. while one was proposed as a 
Microbacterium sp.  Through bioactivity-guided fractionation of chemical extracts, the natural 
products most strongly inhibiting biofilm formation will be isolated using chromatography and 
identified using analytical techniques.  These compounds may prove valuable as agents for 
treatment of biofilm-based infections of P. aeruginosa. 
 
 
 Introduction 
Bacteria produce a variety of compounds that play many roles during their life cycle.  These 
genetically encoded organic molecules may play a direct and vital role in growth and/or 
reproduction.  These required metabolites, including nucleic acids and proteins, are examples of 
primary metabolites.  Bacteria also produce organic compounds that do not play a direct role in 
growth and survival; these are referred to as adaptive metabolites or secondary metabolites.  
Secondary metabolites play various ecological functions, such as interspecies chemical-based 
communication or chemical defense against other microorganisms. 
            Secondary metabolites are also known as natural products.  These chemical compounds 
occupy an important niche in drug discovery and design.  Historically, the majority of clinically 
useful drugs have been obtained from natural sources such as microorganisms associated with 
plants and soil as well as terrestrial macroorganisms (Newmann and Cragg 2007).  Compounds 
from terrestrial organisms play a major role in treating bacterial infections (Table 1).  Today 
such terrestrial sources of drugs are diminishing, due to re-discovery of known compounds and 
increasing bacterial resistance to existing drugs.  
 
Table 1  Selected antibacterial drugs from terrestrial sources 
 
Drug Source Origin Microorganism  
Daptomycin Streptomyces roseosporus soil bacteria 
Streptomycin Streptomyces griseus soil bacteria 
Ampicillin Penicillium chrysogenum soil fungus 
Chloramphenicol Streptomyces venezuelae soil bacteria 
Penicillin Penicillium chrysogenum soil fungus 
Vancomycin Amycolatopsis orientalis soil bacteria 
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Due to the exhaustive and widespread use of antibiotics, bacteria are evolving antibiotic 
resistance via genetic mutations, making existing drugs less effective and creating a public health 
crisis (Levy and Marshall 2004).  Methicillin-resistant Staphylococcus auerus (MRSA) is an 
example of a virulent pathogen that has developed multi-drug resistance.  New antibiotics are 
sought to combat a full array of bacterial strains that are resistant to several 
overused antibiotics.   
            Marine microorganisms are an emerging and underdeveloped source of antibacterial 
compounds that show promising pharmaceutical potential (Fenical and Jensen 2006).  Like 
terrestrial microorganisms, marine microorganisms produce antibacterial compounds that act by 
killing or inhibiting growth of human pathogenic bacteria (Blunt and others 2004).  Marine 
actinobacteria, which are gram positive bacteria that are prevalent in many environments, are of 
interest as natural product drug sources because terrestrial actinobacteria (e.g. Streptomyces sp.) 
are well-known producers of several novel medicinally useful compounds (Goodfellow 1988).  
Limited studies on these marine microorganisms have suggested that marine actinobacteria 
produce secondary metabolites that are often structurally distinct from those produced by 
terrestrial bacteria (Jensen and others 2005). In addition, other groups of marine bacteria such as 
bacilli and proteobacteria have not been extensively explored as sources of new antibacterials 
and hold promise as sources of new drugs (Kawulka and others 2003, Clardy and others 2006).  
The prospect of discovering new antibacterial drugs from the natural products of marine 
microorganisms is great as the ocean contains a great vast of biodiversity covering much of the 
planet.  Marine microorganisms represent a promising, but relatively untapped source of novel 
bacteria-fighting molecules. 
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            In addition to producing antibiotic compounds lethal to bacteria, marine microorganisms 
may also produce biologically active natural products that are not lethal but instead modulate 
bacterial behaviors, such as biofilm formation.  A biofilm is an aggregation of bacteria to 
surfaces including those of lung and other vital tissues. In a response to changes in population 
size, bacteria use autoinducers, chemical signals, to communicate in quorum sensing to 
coordinate behaviors such as biofilm formation among groups of bacteria.  Quorum sensing 
results when a population of bacteria reaches a threshold, with a chemical signal causing a 
change in gene expression and behavior.  Biofilms arise when a mixed culture of bacteria or a 
pure culture releases a polymeric matrix to adhere to abiotic and/or biotic surfaces (Brenda and 
others 2005, Hall-Stoodley and Stoodley 2009).  Biofilms are composed of three essential 
elements: (1) microorganisms, (2) glycocalyx, a complex of exopolysaccharides produced by the 
bacteria and substances from the environment, and (3) the surface.  Planktonic bacteria attach to 
a proximal surface either randomly or directed by chemotaxis and motility.  Bacteria assemble in 
nutrient-rich environments concentrated at a surface due to the equilibrium of bacteria, 
electrostatic and hydrophobic interactions, and van der Waals forces (An and others 2000, 
Carpentier and Cerf 1993, Lawrence and others 1987).  It is the exopolysaccharides and 
exogenous substances gathered from nearby sources that make the association and adhesion 
irreversible.  The synergistic association of bacteria has led to the universal presence of 
ingeniously formed biofilms.  
The sophisticated formation of biofilms has led to several beneficial and detrimental 
effects on bacteria and organisms, including humans.  Although bacterial biofilms may be useful 
for bioremediation and waste management in filtration systems as the bacteria in the biofilm 
interact and rid harmful bacteria, the formation of biofilms is especially detrimental in bacterial 
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infections of humans.  P. aeruginosa is a common bacterial strain that forms a biofilm in the 
airway of patients with cystic fibrosis, and may aggravate nearby cells and cause mortality 
(Moreau-Marquis and others 2008).  The different behaviors between planktonic bacteria and 
bacteria in biofilms, as well as genetically encoded antibiotic resistance have led to low 
antibiotic susceptibility of P. aeruginosa, exemplifying the difficulty in controlling biofilms 
(Bagge and others 2004, Vuong and others 2004, Pearson and others 2006, Jurcisek and Bakaletz 
2007, Lenz and others 2008, Zhang and Mah 2008).  Biofilm-based infections caused by 
Streptococcus mutans are also the root of dental caries and gingivitis. Biofilms on abiotic 
surfaces such as heart valves, pacemakers, and catheters have posed a serious threat in hospital 
settings (Trautner and Darouiche 2004). The potentially destructive effects of biofilms are cause 
for concern in human health. 
Discovering anti-biofilm compounds is of great interest as controlling biofilms is difficult 
and few biofilm inhibiting compounds are known.  Known biofilm inhibitors effective at 
clinically safe concentrations have yet to be discovered (Brown and others 1988).  Biofilms are 
many times more resistant to antibiotics than planktonic cells because bacteria adhered to a 
surface are encased in a thick extracellular matrix that impedes antibiotic penetration and 
biofilm-associated bacteria behave differently than planktonic bacteria through quorum sensing 
via autoinducers.  Additionally, the heterogeneous mixture of bacteria and nutrients from the 
environment in the biofilm matrix make it likely multiple resistance mechanisms exist (Mah and 
O’toole 2001).  Compounds that act as non-lethal inhibitors of biofilm formation are expected to 
pose less selective pressure for evolution of antibacterial resistance as compared to compounds 
that are lethal to bacteria.  It is important to find compounds that control biofilms as inhibition 
may thwart the detrimental impacts of biofilm-associated bacteria on the health of humans.  
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Thus, biofilm inhibitors represent especially promising therapies to be used in conjunction with 
traditional bacteriocidal compounds.   
There is a critical need for new drugs to treat biofilm-based infections.  Recent research 
has uncovered the pharmaceutical potential of marine microorganisms, but much is left to be 
discovered regarding the capacity of these organisms to produce compounds that inhibit bacterial 
survival or biofilm formation (Amador and others 2003).  Thus, we set out to explore the 
hypothesis that Florida marine bacteria produce compounds that may inhibit bacterial 
growth/survival and/or biofilm formation. 
 
Materials and Methods 
Collection and isolation of marine bacteria 
A total of 68 (31 from Northeast Florida and 37 from Key West) 2-3 mL sediment samples were 
collected in sterile 15 mL or 50 mL polypropylene Falcon tubes in coastal northeast Florida and 
the Florida Keys on two separate research expeditions in May 2011 and July 2011, respectively.  
Samples were collected at depths varying from 0.5 to 3.5 meters and kept frozen at -20°C until 
plated on nutrient media for isolation of bacterial strains. 
            Samples were thawed at room temperature, seawater was decanted from sediment 
samples, and 5 mL of sterile seawater was added to samples in a biosafety cabinet to avoid 
introduction of environmental contaminants.  Samples were heat shocked at 55°C for 6 minutes 
to select for heat-resistant bacteria such as actinobacteria, and samples were vortexed gently to 
dissociate bacteria from sand grains.  Fifty µl aliquots of 1:1 and 1:2 dilutions of these samples 
in sterile seawater were deposited on M1 agar plates appended with salt to select for marine 
bacteria (1% potato starch, 0.4% yeast extract, 0.2% peptone, 1.8% agar, 0.0005% 
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cycloheximide, 2.8% Instant Ocean sea salt), ISP2 agar plates (0.4% yeast extract, .1% malt 
extract, 0.4% glucose, 0.18% agar, 0.000001% nalidixic acid, 0.0000001% cycloheximide, and 
0.00000025% nystatin, 2.8% Instant Ocean), and/or Actinomycete Isolation Agar plates ( 2% 
sodium caseinate, 0.001% asparagine, 4% sodium propionate, 0.005%  dipotassium phosphate, 
0.001% ferrous sulfate, 15% agar, 5% glycerol, and 2.8% Instant Ocean sea salt).  The Instant 
Ocean sea salt used in all media contained sodium chloride and other salts: calcium chloride, 
potassium chloride, sodium sulfate, and magnesium chloride.  All media were prepared using 
deionized and filtered water at 18.2 MΩ·cm.  Plates were either kept at room temperature or 
incubated at 30°C and monitored for observation of colonies on plates.  Individual colonies 
observed on plates were repetitively plated onto fresh agar-based media until pure colonies were 
isolated.  For each colony, all antibiotics were omitted from the final media to ensure samples 
were pure cultures and free from contamination with other microorganisms.   
Extraction of natural products from isolated marine bacterial strains 
Two to three isolated colonies were transferred to liquid M1 liquid media (15 mL in a 
sterile 100 mL Erlenmeyer flask covered with a foam stopper and aluminum foil), and incubated 
with shaking at 175-200 rpm for 7-10 days at 30°C.  M1 liquid media consisted of 1% starch, 
0.4% yeast extract, 0.2% peptone, 2% Instant Ocean sea salt 0.004% Fe2(SO4)3x5H2O, 0.01% 
KBr, and 0.1 % CaCO3.  To chemically extract organic compounds produced by bacteria, 1 g of 
Amberlite XAD-7 HP Resin was added to the 15mL liquid cultures and samples incubated with 
shaking (175-200 rpm) at 30°C for 4-6 hours.  The purpose of the resin was to bind with natural 
products present in the liquid bacterial culture.  After incubating samples with resin, the liquid 
media and resin were separated from one another by filtering through 8 layers of 10 cm x 10 cm 
cheesecloth.  Approximately 100 mL of deionized and filtered water at 18.2 MΩ·cm was then 
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poured over the resin and cheesecloth to wash the salts away.  The resin and cheesecloth were 
submerged in 40-60 mL of acetone and incubated overnight at 3°C to elute the organic molecules 
from the resin and into the acetone solution. 
A rotary evaporator was used to remove acetone and residual water by evaporation under 
reduced pressure in a round bottom flask.  Approximately 10-15 mL of methanol was added to 
the remaining traces of liquid extract, extracts were transferred to tared vials, and all remaining 
solvent was evaporated using a centrifugal evaporator (speedvac).  The organic compound 
mixtures were stored at -20°C until ready for bacterial assays. 
Bacterial growth and biofilm inhibition assays 
Each bacterial chemical extract was solubilized with dimethyl sulfoxide (DMSO) to yield 
a concentration of 200 mg of extract per mL of DMSO for bacterial assays to explore the ability 
of the marine organisms to produce growth or biofilm inhibitory compounds.  Tryptic soy broth, 
prepared according to manufacturer’s instructions by MP Biomedicals, LLC, was used to culture 
Pseudomonas aeruginosa (ATCC 27853) or Staphylooccus aureus (ATCC 25923), selected 
human pathogenic bacterial strains. A few frozen cells of P. aeruginosa or S. aureus were 
removed from storage at -80°C and aseptically transferred into 2-3 mL of tryptic soy broth media 
and incubated with shaking for 14-24 hours at 30°C and 175-200 rpm.  
These overnight cultures of S. aureus or P. aeruginosa were diluted by transferring 100 
µl of the bacterial culture to 10 mL of fresh tryptic soy broth.  Four mL of this diluted culture 
were subsequently further diluted by dispensing into 40 mL of tryptic soy broth.  Two-hundred 
µl of this final diluted mixture of media and bacteria was aliquoted to rows A and E of a 96-well 
microtiter plate, and 100 µl of the mixture was aliquoted to remaining wells of a non-tissue 
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culture treated polystyrene 96-well microtiter plate (Corning Costar 3370).  Four µl of 200 
mg/mL chemical extract stocks were aliquoted in duplicate to rows A and E to prepare a final 
concentration of 0.4mg chemical extract per mL of media and cells (Figure 1).  One hundred µl 
of extract/media/cells in rows A and E were removed and added to sequential wells (rows B and 
F) to reduce the concentration of chemical extract by ½, yielding a test concentration of 0.2 mg 
extract/mL of cells and media.  Further aliquoting of 100 µl of material from rows B and F into 
sequential wells of rows C and G, respectively, yielded 0.1 mg extract/mL of cells and media in 
these wells.  Similarly, 0.05mg extract/mL of cells and media were present in rows D and H of 
the microtiter plate.  All dilutions were prepared by mixing via pipetting.  Hence, all extracts 
were tested in duplicate at four concentrations each (0.4, 0.2, 0.1, and 0.05 mg/mL).  No extracts 
were placed in column 11 as it was the dedicated DMSO control containing only bacteria, media, 
and DMSO at the same concentrations as in corresponding treatment wells DMSO with bacteria 
and media prepared the same as the extract dilutions.  No extracts were placed in column 12 as it 
was the dedicated antibiotic control containing 1 µl of gentamicin sulfate (10 mg/mL stock 
concentration) in rows A and E, giving diluted concentrations of 0.1, 0.05, 0.025, and 0.00125 
mg/mL prepared similarly as the extract and DMSO dilutions.  Wells H 11 and 12 were blanks 
that only contained media, to control for background absorbance of media and ensure no 
contamination of media.  The 96-well plates were wrapped in parafilm and incubated overnight 
at 30°C without shaking.  The following day plates were read at 630 nm with a microplate reader 
to quantify bacterial growth/death (Figure 1). 
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Figure 1  Template of 96-well plate used to test for bioactivity of NEF and KW chemical extracts 
against pathogenic strains of P. aeruginosa or S. aureus  
All above-described assays were conducted in duplicate on at least two separate occasions.  
Average inhibition of bacterial growth was calculated by comparing the absorption at 630 nm for 
all replicate treatment samples to the absorption recorded for replicate controls according to the 
formula below, and standard deviations computed using Microsoft Excel.  For purposes of 
pursuing the most promising potential drug leads, only chemical extracts inhibiting bacterial 
Column 12 = 1 µl gentamycin + bacteria 
Rows A & E = 200 µl of media/bacteria + 4 µl NEF or KW DMSO extract 
Rows B-D & E-G = 100 µl of media/bacteria 
 
  Column 11 = DMSO + bacteria 
BLANK 
Column 1-10 = Treatment (NEF or KW extracts) 
    H 11&12 (BLANK) = 100 µl of media 
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growth or biofilm formation by at least 25% relative to controls were deemed sufficiently 
bioactive for pursuit of compounds responsible for observed biological activities.   
% growth inhibition = (1 - average absorption of treatments/average absorption of controls) x 100% 
            Chemical extracts were evaluated for capability to inhibit biofilm formation by following 
a previously reported protocol (Meritt and others 2011).  Planktonic bacteria were removed from 
each of the above microtiter wells by shaking to remove liquid from microtiter plates and then 
submerging plates in tap water.  The water was then removed by shaking, and remaining surface-
adhered bacteria were then stained with crystal violet.  To stain, 125 µl of 0.1% (m/v) aqueous 
crystal violet solution was aliquoted to each well and incubated at room temperate for 10-15 min.  
Crystal violet solution not bound to cells was removed by inverting the plate and shaking, 
followed by washing wells by dipping into a basin of water.  Plates were then air dried and 
inverted at an angle at 23°C overnight at room temperature.  Two hundred µl of a 30% acetic 
acid solution was added to each well and incubated for 10-15 minutes at room temperature to 
solubilize the crystal violet dye.  After mixing by pipetting, 125 µl of the acetic acid/crystal 
violet solution from each well was transferred to an optically clear flat-bottom 96-well plate.  
The optical density (OD) of treatments and controls was measured at 540 nm to assess the 
amount of crystal violet present in each well and thus quantify percent inhibition of biofilm 
formation for chemical extract treatments relative to no extract controls.  For all biofilm 
inhibition assays, average inhibition of bacterial biofilm formation was calculated analogously to 
growth inhibition assays.  Compounds that inhibited growth of bacteria were expected to also 
inhibit biofilm formation in this assay, since lower cell numbers correspond to reduced quantities 
of bacteria available for biofilm formation.  Hence, for all chemical extracts found to inhibit 
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biofilm formation, we confirmed that no growth inhibition was observed (as determined by the 
growth inhibition assay described above).  
Identification of bacterial strains producing biofilm inhibitors 
The genomic DNA of bacteria producing bioactive compounds (as determined by above-
described assays) was purified using the Qiagen Blood and Tissue DNA Isolation kit, following 
the manufacturer protocol for gram-positive bacteria and eluting DNA with 100 uL of Buffer AE 
instead of the manufacturer-recommended 200 uL of AE Buffer.  This reduction in buffer 
volume was used for bacterial strain identification (Gontang and others 2007).  These universal 
primers had the following sequences:  ―27F‖ GAGTTTGATCCTGGCTCA  and ―1385R‖ 
CGGTGTGTRCAAGGCCC. 
The PCR reaction to amplify 16S rDNA in identification of bacterial species was carried 
out with a total volume of 25 uL and PCR reaction mix consisting of 4.5 uL of New England 
Biolabs (NEB) Taq polymerase, 2.7 uL of each primer (concentration of stock?), 5.58 uL of 
DNA template, 22.5 uL of NEB Thermopol buffer.  The thermocycler was programmed to run 
the following cycles:  2 min at 95°C, followed by 30 cycles of 1 min at 95 °C, 1 min at 52°C, and 
1.5 min at 72°C, and a final extension step at 72°C for 10 minutes.  PCR success was confirmed 
by detection of ~1500 bp bands of amplified 16S rRNA gene fragments through gel 
electrophoresis.  Five µl of the PCR reaction product and 2 µl of loading dye was loaded onto a 
0.7% agarose gel with ethidium bromide at a voltage of 100-110 V for 30 minutes.  Six mL of 
DNA ladder (GeneRuler 1kB Plus, ThermoScientific) were also run on the gel.   
PCR products of ~1500 bp were purified using the QIAGEN QIAquick PCR Purification 
kit, following manufacturer protocols.  Selected purified PCR products were submitted to 
Eurofins Operon (Huntsville, Alabama) for sequencing, using the same primers for sequencing 
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as were used in PCR.  DNA sequences were assembled using Geneious software (Drummond 
and others 2011).  To identify bacterial strains, this DNA sequence information was searched 
against the National Center for Biotechnology Information (NCBI) Basic Local Alignment 
Search Tool (BLAST) nucleotide database of 16S rRNA sequences (Altschul and others 1990).   
 
Results 
Northeast Florida and the Florida Keys are both rich in culturable marine microorganisms.  A 
total of 22 bacterial strains were isolated from coastal waters of northeast Florida and 35 
bacterial strains from the Florida Keys were isolated (Figures 2a, 2b, Table 2) using the three 
medias employed in the current study. 
 
 
a   
 
 b 
 
Figure 2a, 2b  Mixed colonies of KW bacteria grown on M1 media without antifungal agents   
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Table 2  Location and gross morphology of Northeast Florida and Key West isolated 
bacterial colonies (NEF = Northeast Florida, KW = Key West) 
Sample 
ID: Location (GPS) 
Gross morphology on M1 agar 
media 
NEF 1 Not recorded off white, smooth, glossy 
NEF 2 30° 23' 39" N, 81° 24' 4" W peach, glossy, smooth 
NEF 3 30° 23' 39" N, 81° 24' 4" W off white, smooth, cloudy 
NEF 4 30° 23' 39" N, 81° 24' 4" W off white, smooth, glossy 
NEF 5 30° 24' 60" N, 81° 24' 23" W brown, fuzzy  
NEF 6 Not recorded  hunter green, fuzzy, powdery 
NEF 7 30° 23' 39" N, 81° 24' 4" W off white, smooth, glossy 
NEF 8 30° 23' 39" N, 81° 24' 4" W yellow, smooth 
NEF 9 30° 23' 39" N, 81° 24' 4" W hunter green, fuzzy 
NEF 10 30° 24' 60" N, 81° 24' 23" W peach, smooth, glossy 
NEF 11 30° 23' 39" N, 81° 24' 4" W hunter green, powdery, fuzzy 
NEF 12 30° 23' 39" N, 81° 24' 4" W off white, cloudy, glossy 
NEF 13 30° 23' 39" N, 81° 24' 4" W brown, flat, powdery 
NEF 14 30° 24' 60" N, 81° 24' 23" W brown dots, flat, powdery 
NEF 15 30° 27' 32" N, 81° 24' 47" W off white, smooth 
NEF 16 30° 24' 60" N, 81° 24' 23" W pale green, fuzzy 
NEF 17 30° 23' 39" N, 81° 24' 4" W brown, powdery 
NEF 18 30° 24' 26" N, 81° 24' 36" W white, clear 
NEF 19 Not recorded peach, cloudy, glossy 
NEF 20 30° 23' 39" N, 81° 24' 4" W peach, smooth, glossy 
NEF 21 Not recorded off white, smooth, glossy 
NEF 22 30° 23' 39" N, 81° 24' 4" W yellow, smooth 
KW 1 24° 37' 40" N, 82° 52' 22" W yellow, fuzzy 
KW 2 24° 37' 40" N, 82° 52' 22" W clear, smooth, branching 
KW 3 24° 31' 20" N, 82° 58' 11" W light hunter green, fuzzy 
KW 4 24° 3' 45" N, 82° 7' 28" W cloudy white, branching 
KW 5 
 
white, fuzzy 
KW 6 24° 37' 40" N, 82° 52' 22" W light hunter green, fuzzy 
KW 7 24° 31' 20" N, 82° 58' 11" W cloudy white, branching 
KW 8 24° 37' 40" N, 82° 52' 22" W off white, smooth, glossy 
KW 9 24° 31' 20" N, 82° 58' 11" W yellow, smooth 
KW 10 24° 3' 45" N, 82° 7' 28" W white, smooth, branching, dots 
KW 11 24° 31' 20" N, 82° 58' 11" W orange, smooth, glossy 
KW 12 24° 37' 40" N, 82° 52' 22" W pale yellow, cloudy 
KW 13 24° 3' 45" N, 82° 7' 28" W light hunter green, fuzzy 
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KW 14 24° 37' 40" N, 82° 52' 22" W orange, smooth, glossy 
KW 15 24° 31' 20" N, 82° 58' 11" W white, cloudy, fuzzy 
KW 16 24° 37' 40" N, 82° 52' 22" W light hunter green, fuzzy 
KW 17 24° 37' 40" N, 82° 52' 22" W off white, smooth, cloudy 
KW 18 24° 37' 40" N, 82° 52' 22" W pale yellow, cloudy 
KW 19 24° 37' 36" N, 82° 52' 3" W white, smooth, cloudy 
KW 20 24° 37' 40" N, 82° 52' 22" W white, smooth, cloudy, glossy 
KW 21 24° 3' 45" N, 82° 7' 28" W white, smooth, cloudy 
KW 22 24° 37' 40" N, 82° 52' 22" W white, clear 
KW 23 24° 3' 45" N, 82° 7' 28" W white, clear, smooth, dots 
KW 24 24° 37' 40" N, 82° 52' 22" W white, smooth, clear, skinny lines 
KW 25 24° 3' 45" N, 82° 7' 28" W off white, smooth, cloud 
KW 26 24° 3' 45" N, 82° 7' 28" W hunter green, fuzzy, powdery 
KW 27 24° 37' 40" N, 82° 52' 22" W brown, fuzzy 
KW 28 24° 31' 20" N, 82° 58' 11" W brown, fuzzy, powdery 
KW 29 24° 37' 40" N, 82° 52' 22" W off white, cloudy,  branching 
KW 30 24° 37' 40" N, 82° 52' 22" W brown, fuzzy 
KW 31 24° 37' 40" N, 82° 52' 22" W clear white, smooth ,dots  
KW 32 24° 37' 40" N, 82° 52' 22" W off white, cloudy, smooth 
KW 33 24° 37' 40" N, 82° 52' 22" W off white, clear, smooth  
KW 34 24° 31' 20" N, 82° 58' 11" W brown, fuzzy 
KW 35 24° 3' 45" N, 82° 7' 28" W brown, fuzzy 
 
All 57 isolated strains were chemically extracted and resulting extracts evaluated for inhibition 
of growth of two model human pathogens, the gram-positive bacterium S. auerus and gram-
negative P. aeruginosa.  No chemical extracts showed significant inhibition of bacterial growth 
in S. auerus or P.aeruginosa assays (Table 2, data not shown).  Further, none of the 57 chemical 
extracts significantly inhibited biofilm formation of S. aureus.  However, significant inhibition of 
biofilm formation was observed for chemical extracts of 7 bacterial strains against P. 
aeruginosa.  These strains correspond to NEF 3, NEF 4, NEF8, NEF 20, KW 2, KW 13, and KW 
17 (Table 2, Figure 3).  Of the 7 marine bacterial strains producing compounds inhibitory toward 
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biofilm formation, 5 of the strains most strongly inhibitory toward biofilm formation were 
identified (Table 3).  
 
Figure 3  Representative isolated pure colony of NEF bacteria grown on M1 media without 
antifungal agents  
Table 3  Percent inhibition of P. aeruginosa (PA) and S. aureus (SA) biofilm formation of at 
least one bacterium by chemical extracts from NEF and KW marine microorganisms (SA n=4, 
*n=2; PA n=4).  (Only those chemical extracts inhibiting biofilm formation by at least 25% 
(relative to no-extract controls) on average are included.  None of the evaluated 57 marine 
chemical extracts inhibited bacterial growth by at least 25%) 
Chemical 
extract 
sample # 
 
 
Species 
assignment 
 
 
 
avg % 
biofilm 
inhibition in 
SA ± 1 SD 
 
avg % 
bacteria 
growth 
inhibition 
in SA± 1 
SD 
avg % 
biofilm 
inhibition 
in PA ± 1 
SD 
 
avg % 
bacteria 
growth 
inhibition 
in PA± 1 
SD 
NEF 3 Bacillius sp.  0 ± 123 2.5 ± 21 61± 14 0 ± 24 
NEF 4 Bacillius sp.  0 ± 129 0 ± 19 62± 17 0 ± 17 
NEF 8 
Microbacterium 
sp. 4 ±16* 0 ± 71* 52± 18 7 ± 28 
NEF 20 Bacillius sp.  0 ± 896 7 ± 7 51± 14  0 ± 5 
KW 2 NA 0 ± 83 0 ± 42 30± 20 4 ± 22 
KW 13 NA 0 ± 59 0 ± 30 39± 17 0 ± 14 
KW 17 Bacillius sp.  0 ± 22* 0 ± 8* 36± 24 0 ± 16 
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Figure 4  Average percent inhibition of biofilm formation of P. aeruginosa by chemical extracts 
from NEF and KW microorganisms (n=4, chemical extracts tested at final concentration of 0.4 
mg/mL of bacteria and media) 
Genomic DNA was isolated from all strains and this DNA subjected to PCR using well-
established primers for amplification of 16S rRNA gene sequences (Gontang and others 2007).  
Agarose gel electrophoresis indicated PCR amplicons at the expected size of ~1500 bp, 
indicating successful amplification of 16S rDNA (Figure 3).  This DNA was purified and 
commercially sequenced for five strains producing compounds strongly inhibitory toward 
biofilm formation (Table 3).  Using the National Center for Biotechnology Information (NCBI) 
Basic Local Alignment Search Tool (BLAST), the amplified sequences were found to match 
most closely with strains shown in Table 3 (Altschul and others 1990).    
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Table 4  16S rRNA sequence-based identification of select samples producing compounds 
strongly inhibitory toward P. aeruginosa biofilm formation 
Chemical 
extract 
sample # 
Species assignment Closest relative 
% 
identity 
NEF 3 Bacillius sp.   Bacillus idriensis  98 
NEF 4 Bacillius sp.  Bacillus idriensis  98 
NEF 8 Microbacterium sp.  Microbacterium esteraromaticum  96 
NEF 20 Bacillius sp.  Bacillus idriensis  98 
KW 17 Bacillius sp.   Bacillus idriensis  98 
 
 
Figure 5  0.7% agarose gel showing amplification of a targeted ~1500bp 16S rDNA sequence for 
representative KW bacteria with DNA Ladder Fermentas Gene Ruler Plus in first and last lanes 
of gel (Samples KW 15-20, C=control of 16S rDNA amplified from Nocardiopsis sp. genomic 
DNA, B=blank) 
Discussion 
A total of 57 bacterial strains were isolated from Florida marine sediments:  22 from 
northeast Florida and 35 from Key West, which alludes to the substantial marine microbial 
diversity present in these regions.  Upon further investigation of the capacity of these marine 
organisms to produce compounds inhibitory toward human pathogenic bacteria growth and/or 
biofilm formation, seven marine strains were found to produce compounds reducing 
Pseudomonas aeruginosa biofilm formation by at least 30% relative to controls.  This 
corresponds to 12.3% (7 out of 57) marine strains in our study yielding chemical extracts capable 
    15        16          17         18         19         20          C           B   
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of impeding biofilm formation of P. aeruginosa, a human pathogen highly prevalent in lung 
infections of patients with cystic fibrosis and pneumonia.  Our findings give insight to the 
biomedical potential of marine microorganisms as sources of biofilm-inhibiting compounds that 
may prove useful as human therapeutics, and suggest that further pursuit of Florida marine 
microorganisms as sources of human therapeutics is in order.  Our results also raise the question 
of the ecological function of these biofilm-inhibiting compounds.  It is plausible that the 
organisms employ biofilm-inhibiting compounds as chemical defenses, to ward off competing 
co-occurring microorganisms.  Future studies may explore such hypotheses.   
Sessile biofilm-associated bacteria behave differently than the same bacteria in  
planktonic states, and traditional growth inhibitory antimicrobial agents are far less effective in 
eradicating infections of biofilm-associated bacteria than in combatting planktonic bacterial 
infections.  Biofilms are inherently resistant to antibiotics due to three possible explanations: (1) 
the agent not penetrating the biofilm, (2) the slow-growth rate or starved state of biofilm-
associated bacteria, and/or (3) extreme microenvironmental conditions and altered gene 
expression patterns (Bagge and others 2004, Vuong and others 2004; Pearson and others 2006; 
Jurcisek and Bakaletz, 2007; Lenz and others 2008; Zhang and Mah 2008).  The first explanation 
postulates that the glycocalyx retards or prevents the antibiotic agent from fully penetrating the 
biofilm and reaching the bacterial cells.  The penetration of the biocide is dependent upon not 
only the agent, but also the biofilm structure, which is why the discovery of an effective anti-
biofilm agent is expected to be of immense value (Ceri and others 1999, Schierholz and others 
1999).  The second hypothesis suggests that due to a higher density of cells in the biofilm, 
nutrients and resources are limited.  This causes a slow-growing rate or starved state in which 
potent biocides are less effective due to low susceptibility (Brown and others 1988).  The final 
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hypothesis explains the inherent resistance of biofilms is due to the attached bacteria in biofilms 
behaving differently as a result of different gene expression in an extreme microenvironment 
(Bagge and others 2004, Vuong and others 2004; Pearson and others 2006; Jurcisek and 
Bakaletz, 2007; Lenz and others 2008; Zhang and Mah 2008), and these gene expression 
differences enhancing resistance to antibiotics.  Addressing the former has spurred the search for 
compounds helpful for the treatment of biofilm-associated bacteria, including P. aeruginosa.  
Thus, our results contribute to efforts to identify biofilm-inhibiting drugs by supporting marine 
bacteria as a promising source of biofilm inhibitors.  Our study is one of only a handful exploring 
marine bacteria as sources of biofilm inhibitors, and expands to explore sources of anti-biofilm 
compounds (Assmann and others 2000, Chanas and others 1997, Sullivan and others 1981, 
Manzo and others 2011). 
In addition to providing potential drug leads, our findings may also help us to understand 
how P.aeruginosa forms biofilms.  The glycocalyx production is thought to be surface activated, 
which is responsible for biofilm formation  (Davies and others 1993).  The algC gene is an 
important regulation point thought to control attachment.  The upregulation and expression of 
algC induced by environmental factors, such as osmoregularity and high oxygen tensions, after 
attachment is 19 fold greater in attached bacteria than free floating bacteria (Davies and others 
1993, Davies and Greesey 1995, Devault and others 1989, Devault and others 1990).  Because it 
is assumed that the algC gene is important to quorum sensing and biofilm formation, the 
compounds produced by the 7 Florida microorganisms may be involved in modulating the algc 
gene and/or products to disassociate P. aeruginosa biofilms.   
Marine microorganisms may produce anti-biofilm compounds due to selective pressures 
that favored the evolution of pathways for production of secondary metabolites to inhibit biofilm 
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formation.  Marine sponges present in association with marine sediment have been founds to 
produce compounds that inhibit biofilms (Assmann and others 2000, Chanas and others 1997).  It 
is predicted that selective pressures, including predators, competition for space and resources, 
and surface fouling (biofilms), favored the evolution of biochemical pathways for the generation 
of bioactive secondary metabolites (Assmann and others 2000, Chanas and others 1997, Sullivan 
and others 1981, Manzo and others 2011).  This supports the possibility of marine bacterial 
bioactive secondary metabolites as chemical defenses against biofilms, a hypothesis that may be 
explored in the future for our marine bacteria.   
Further analysis and identification of specific biofilm-inhibitory compounds from the 
seven select extracts may give insight to how biofilms are inherently resistant to traditional 
antibiotics and how the integrity of the biofilm is formed and disassembled.  Identifying the 
bioactive compounds may also facilitate determination of how gene expression is altered during 
biofilm formation and dispersal or the mechanism of an effective compounds to cause 
autodispersion, displacing the aggregation of bacteria from the adhered surface and 
disassembling the biofilm, to increase antibiotic sensitivity to biofilm bacteria.  The natural 
products may also enable us to better understand the autoinducers involved in the chemical 
signaling (e.g. quorum sensing) for planktonic bacteria to coordinate behaviors and form 
biofilms and how the bacteria in the biofilm behave differently than free-living bacteria. These 
findings offer great biomedical applications as they may be used in drug design to develop an 
effective natural product biofilm inhibitor. 
The microorganisms exhibiting the strongest ability to produce biofilm inhibiting 
compounds (Figure 4) will be further explored to isolate and identify specific components of the 
mixtures using various analytical tests: chromatography to isolate bioactive compounds, and 
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NMR spectroscopy and mass spectrometry to determine the complete chemical structure of such 
compounds.  Additionally, bacteria from more locations throughout Florida may be isolated and 
explored for biofilm inhibitory compounds, as well as subjecting bacteria to various conditions 
(e.g. different media and antifungal agents) and co-cultivation with other bacteria in an effort to 
stimulate production of further bioactive natural products.  These co-cultivation and media 
manipulation strategies have previously proven effective in activating unexpressed biochemical 
pathways and hold promise for further tapping into the potential of marine bacteria to yield new 
drugs (Onaka and others 2011, Pettit 2009, Scherlach and Hertweck 2009, Zuck and others 2011, 
Angell and others 2006).  Further computer aided analysis and design may be used to identify the 
biochemical pathway of how the natural products are produced by microorganisms and synthesis 
of lead compounds responsible for inhibiting biofilm formation.  
This study supports natural product drug discovery from marine bacteria and highlights 
the immense untapped potential of coastal Florida marine bacteria as sources of biofilm 
inhibitory compounds.  Finding 7 marine microorganisms producing natural products that inhibit 
biofilm formation may help to address the multifaceted problem of understanding biofilm 
formation mechanisms and discovering effective and clinically useful antimicrobial agents to 
inhibit biofilm formation.  Much has yet to be discovered in this area, and the forecast is clear for 
finding novel marine natural products to combat biofilm-based infections. 
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